MGX (Metagenomi Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.32
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Tariff Resilience Score?

Metagenomi Therapeutics MGX +6.45% 10 Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,367 Biotechnology companies, Metagenomi Therapeutics ranks better than 75.93% on this metric.

Metagenomi Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Metagenomi Therapeutics has Biotech firm with some global supply chain exposure. Industry-specific exemptions and strong R&D focus provide some resilience. Past tariffs have had a moderate impact on operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Metagenomi Therapeutics might have Average Resilient.

Metagenomi Therapeutics  (NAS:MGX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Metagenomi Therapeutics Tariff Resilience Score Related Terms

MGX vs KALA, HYPD, APLM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's Tariff Resilience Score falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Metagenomi Therapeutics (MGX) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Metagenomi Therapeutics ranks #329 out of 1367 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Metagenomi Therapeutics' Tariff Resilience Score too high?
Metagenomi Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Metagenomi Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Metagenomi Therapeutics ranks #329 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Tariff Resilience Score compare to KALA and HYPD?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #329 out of 1367 companies for Tariff Resilience Score. This places Metagenomi Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Metagenomi Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metagenomi Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price